tiprankstipranks
Advertisement
Advertisement

AGIO Stock Latest News

Agios Pharmaceuticals Signals Momentum Amid Ongoing Losses
Company AnnouncementsAgios Pharmaceuticals Signals Momentum Amid Ongoing Losses
25d ago
AGIO
Agios Pharmaceuticals price target raised to $52 from $46 at Citi
PremiumThe Fly
Agios Pharmaceuticals price target raised to $52 from $46 at Citi
1M ago
AGIO
Agios: Buy Rating Reiterated on Strong AQVESME Uptake and Pipeline Progress, Price Target Maintained at $46
PremiumRatings
Agios: Buy Rating Reiterated on Strong AQVESME Uptake and Pipeline Progress, Price Target Maintained at $46
1M ago
AGIO
Agios: Strong Mitapivat Launch and Growing Patient Uptake Drive Confident Buy Rating
PremiumRatings
Agios: Strong Mitapivat Launch and Growing Patient Uptake Drive Confident Buy Rating
1M ago
AGIO
Agios Pharmaceuticals price target raised to $55 from $52 at H.C. Wainwright
PremiumThe Fly
Agios Pharmaceuticals price target raised to $55 from $52 at H.C. Wainwright
1M ago
AGIO
Agios Pharmaceuticals reports Q2 EPS ($1.69), consensus ($1.66)
PremiumThe FlyAgios Pharmaceuticals reports Q2 EPS ($1.69), consensus ($1.66)
1M ago
AGIO
AGIO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
AGIO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
1M ago
AGIO
Agios Pharmaceuticals: Buy Rating Reaffirmed with Unchanged $46 Price Target on Mitapivat Sickle Cell Catalyst and AQVESME Thalassemia Launch Momentum
Premium
Ratings
Agios Pharmaceuticals: Buy Rating Reaffirmed with Unchanged $46 Price Target on Mitapivat Sickle Cell Catalyst and AQVESME Thalassemia Launch Momentum
2M ago
AGIO
Agios Pharmaceuticals price target lowered to $52 from $54 at H.C. Wainwright
PremiumThe Fly
Agios Pharmaceuticals price target lowered to $52 from $54 at H.C. Wainwright
2M ago
AGIO
Morning Movers: Equifax sinks following second quarter earnings
PremiumThe Fly
Morning Movers: Equifax sinks following second quarter earnings
2M ago
GM
DHI
Agios Pharmaceuticals down 13% at $34.75 on topline results from tebapivat trial
PremiumThe Fly
Agios Pharmaceuticals down 13% at $34.75 on topline results from tebapivat trial
2M ago
AGIO
Agios Pharmaceuticals announces topline results from tebapivat trial
PremiumThe Fly
Agios Pharmaceuticals announces topline results from tebapivat trial
2M ago
AGIO
Agios Pharmaceuticals rises 13.5%
PremiumThe FlyAgios Pharmaceuticals rises 13.5%
2M ago
AGIO
Mitapivat’s Priority Review in Sickle Cell Disease Supports First-in-Class 2026 Launch, Long-Term Growth; Buy Rating and $54 Price Target Maintained
Premium
Ratings
Mitapivat’s Priority Review in Sickle Cell Disease Supports First-in-Class 2026 Launch, Long-Term Growth; Buy Rating and $54 Price Target Maintained
2M ago
AGIO
Leerink sees Priority Review designation as positive sign for Agios’ mitapivat
Premium
The Fly
Leerink sees Priority Review designation as positive sign for Agios’ mitapivat
2M ago
AGIO
H.C. Wainwright sees FDA Priority Review as positive signal for Agios’ mitapivat
PremiumThe Fly
H.C. Wainwright sees FDA Priority Review as positive signal for Agios’ mitapivat
2M ago
AGIO
Agios Pharmaceuticals rises 12.9%
PremiumThe Fly
Agios Pharmaceuticals rises 12.9%
2M ago
AGIO
Agios Pharmaceuticals price target raised to $46 from $40 at BofA
PremiumThe Fly
Agios Pharmaceuticals price target raised to $46 from $40 at BofA
2M ago
AGIO
Agios Pharmaceuticals price target raised to $41 from $36 at Truist
PremiumThe Fly
Agios Pharmaceuticals price target raised to $41 from $36 at Truist
2M ago
AGIO
Agios Pharmaceuticals price target raised to $32 from $28 at RBC Capital
PremiumThe FlyAgios Pharmaceuticals price target raised to $32 from $28 at RBC Capital
2M ago
AGIO
Agios Pharmaceuticals granted priority review for mitapivat sNDA
Premium
The Fly
Agios Pharmaceuticals granted priority review for mitapivat sNDA
2M ago
AGIO
Agios Pharma Shareholders Expand Equity Plan, Reelect Directors
Premium
Company Announcements
Agios Pharma Shareholders Expand Equity Plan, Reelect Directors
3M ago
8K
AGIO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >